Literature DB >> 29944195

Recommendations on multidisciplinary management of elective surgery in people with haemophilia.

M A Escobar1, A Brewer2, H Caviglia3, A Forsyth4, V Jimenez-Yuste5, L Laudenbach6, S Lobet7, P McLaughlin8, J O O Oyesiku9, E C Rodriguez-Merchan10, A Shapiro11, L P Solimeno12.   

Abstract

Planning and undertaking elective surgery in people with haemophilia (PWH) is most effective with the involvement of a specialist and experienced multidisciplinary team (MDT) at a haemophilia treatment centre. However, despite extensive best practice guidelines for surgery in PWH, there may exist a gap between guidelines and practical application. For this consensus review, an expert multidisciplinary panel comprising surgeons, haematologists, nurses, physiotherapists and a dental expert was assembled to develop practical approaches to implement the principles of multidisciplinary management of elective surgery for PWH. Careful preoperative planning is paramount for successful elective surgery, including dental examinations, physical assessment and prehabilitation, laboratory testing and the development of haemostasis and pain management plans. A coordinator may be appointed from the MDT to ensure that critical tasks are performed and milestones met to enable surgery to proceed. At all stages, the patient and their parent/caregiver, where appropriate, should be consulted to ensure that their expectations and functional goals are realistic and can be achieved. The planning phase should ensure that surgery proceeds without incident, but the surgical team should be ready to handle unanticipated events. Similarly, the broader MDT must be made aware of events in surgery that may require postoperative plans to be changed. Postoperative rehabilitation should begin soon after surgery, with attention paid to management of haemostasis and pain. Surgery in patients with inhibitors requires even more careful preparation and should only be undertaken by an MDT experienced in this area, at a specialized haemophilia treatment centre with a comprehensive care model.
© 2018 The Authors Haemophilia Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  elective surgery; haemophilia; multidisciplinary; physical therapy; planning; recommendations

Mesh:

Year:  2018        PMID: 29944195     DOI: 10.1111/hae.13549

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  11 in total

1.  Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study.

Authors:  Brendan Kleiboer; Marcus A Layer; Lorraine A Cafuir; Adam Cuker; Miguel Escobar; M Elaine Eyster; Eric Kraut; Andrew D Leavitt; Steven R Lentz; Doris Quon; Margaret V Ragni; Dianne Thornhill; Michael Wang; Nigel S Key; Tyler W Buckner
Journal:  J Thromb Haemost       Date:  2022-02-08       Impact factor: 5.824

2.  Total Hip Arthroplasty in Patients With Classic Hemophilia: A Matched Comparison of 90-Day Outcomes and 5-Year Implant Survival.

Authors:  Stephen M Gillinov; Patrick J Burroughs; Harold G Moore; Lee E Rubin; David B Frumberg; Jonathan N Grauer
Journal:  J Arthroplasty       Date:  2022-03-04       Impact factor: 4.435

3.  Project GYM: A randomized feasibility study investigating effect on motivation of personal trainer-led exercise in young men with hemophilia.

Authors:  Paul McLaughlin; Mike Holland; Sandra Dodgson; Kate Khair
Journal:  Res Pract Thromb Haemost       Date:  2021-11-26

4.  Definition and Coordination of Roles and Responsibilities Among Cancer Center Clinic and Research Personnel.

Authors:  Simon J Craddock Lee; Torsten Reimer; Sandra Garcia; Erin L Williams; Mary West; Tobi Stuart; David E Gerber
Journal:  JCO Oncol Pract       Date:  2019-10-07

5.  PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.

Authors:  Miguel Escobar; James Luck; Yevhenii Averianov; Jonathan Ducore; Maria Fernanda López Fernández; Adam Giermasz; Daniel P Hart; Janna Journeycake; Craig Kessler; Cindy Leissinger; Johnny Mahlangu; Laura Villarreal Martinez; Wolfgang Miesbach; Ismail Haroon Mitha; Doris Quon; Mark T Reding; Jean-François Schved; Oleksandra Stasyshyn; Kateryna V Vilchevska; Michael Wang; Jerzy Windyga; W Allan Alexander; Ahmad Al-Sabbagh; Daniel Bonzo; Ian S Mitchell; Thomas A Wilkinson; Cédric Hermans
Journal:  Haemophilia       Date:  2021-10-06       Impact factor: 4.263

Review 6.  The role of orthopaedic surgery in haemophilia: current rationale, indications and results.

Authors:  E Carlos Rodríguez-Merchán
Journal:  EFORT Open Rev       Date:  2019-05-10

Review 7.  Surgical Risk on Patients with Coagulopathies: Guidelines on Hemophiliac Patients for Oro-Maxillofacial Surgery.

Authors:  Luigi Laino; Marco Cicciù; Luca Fiorillo; Salvatore Crimi; Alberto Bianchi; Giulia Amoroso; Ines Paola Monte; Alan Scott Herford; Gabriele Cervino
Journal:  Int J Environ Res Public Health       Date:  2019-04-17       Impact factor: 3.390

8.  Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures.

Authors:  Florian Kocher; Andreas Seeber; Johannes Kerschbaumer; Stefan Schmidt; Dominik Wolf; Clemens Feistritzer
Journal:  Ther Adv Hematol       Date:  2021-03-31

9.  Multidisciplinary Team Care of Patients with Hemophilic Arthropathy: A Qualitative Assessment of Contemporary Practice in the UK and Canada : Canada/UK: MDT Practices for Hemophilia.

Authors:  Jean St-Louis; Pratima Chowdary; Gerry Dolan; Dawn Goodyear; Karen Strike; Debra Pollard; Jerry Teitel
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

10.  Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles.

Authors:  Chun-Yu Chen; Dominic M Tran; Alex Cavedon; Xiaohe Cai; Raj Rajendran; Meghan J Lyle; Paolo G V Martini; Carol H Miao
Journal:  Mol Ther Nucleic Acids       Date:  2020-04-07       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.